Relationship between Darbepoetin and Intermittent Hypoxemia in Preterm Infants.

OBJECTIVE: In the Darbepoetin to Improve Red Cell Mass and Neuroprotection in Preterm Infants Trial (Darbe; NCT03169881), infants <29wks gestation receiving darbepoetin were less likely to develop bronchopulmonary dysplasia (BPD) and had higher hematocrit and red blood cell counts (RBC) suggesting that darbepoetin may augment tissue oxygen delivery and thereby improve respiratory outcomes. Intermittent hypoxemia (IH) is associated with an increased risk of BPD, and it is possible that darbepoetin reduces BPD by attenuating IH. STUDY DESIGN: A subcohort of 94 infants enrolled in Darbe were retrospectively analyzed. Number, duration, nadir and total time with IH <90% and <80% were identified through 42 days of age on continuous oxygen saturation recordings. Hematocrit and RBC counts were documented at days 14 and 42. RESULTS: Darbepoetin infants had a higher hematocrit at day 42 and there were fewer IH events <80% with a higher hematocrit (β=-1.51, 95% CI (-2.67, -0.36), p=0.03). However, the effect of darbepoetin supplementation on patterns of IH was limited to a significantly higher nadir (less severe) for IH <80% (β=-0.02, 95% CI (-0.04, 0), p=0.04). CONCLUSIONS: Darbepoetin increases hematocrit but only modestly improves oxygen stability in preterm infants.

Authors

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1159/neo/adsag043
Primary Topic
Neonatal Respiratory Health Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Relationship between Darbepoetin and Intermittent Hypoxemia in Preterm Infants.

Juliann Marie Di Fiore, Namasivayam Ambalavanan, Anna Maria Hibbs, Nori Mercuri Minich et al.
2 links
PubMed
Neonatal Respiratory Health Research
article

Relationship between Darbepoetin and Intermittent Hypoxemia in Preterm Infants.

Juliann Marie Di Fiore, Namasivayam Ambalavanan, Anna Maria Hibbs, Nori Mercuri Minich, Richard J Martin, Yuxi Zhu
article en

Abstract

OBJECTIVE: In the Darbepoetin to Improve Red Cell Mass and Neuroprotection in Preterm Infants Trial (Darbe; NCT03169881), infants <29wks gestation receiving darbepoetin were less likely to develop bronchopulmonary dysplasia (BPD) and had higher hematocrit and red blood cell counts (RBC) suggesting that darbepoetin may augment tissue oxygen delivery and thereby improve respiratory outcomes. Intermittent hypoxemia (IH) is associated with an increased risk of BPD, and it is possible that darbepoetin reduces BPD by attenuating IH. STUDY DESIGN: A subcohort of 94 infants enrolled in Darbe were retrospectively analyzed. Number, duration, nadir and total time with IH <90% and <80% were identified through 42 days of age on continuous oxygen saturation recordings. Hematocrit and RBC counts were documented at days 14 and 42. RESULTS: Darbepoetin infants had a higher hematocrit at day 42 and there were fewer IH events <80% with a higher hematocrit (β=-1.51, 95% CI (-2.67, -0.36), p=0.03). However, the effect of darbepoetin supplementation on patterns of IH was limited to a significantly higher nadir (less severe) for IH <80% (β=-0.02, 95% CI (-0.04, 0), p=0.04). CONCLUSIONS: Darbepoetin increases hematocrit but only modestly improves oxygen stability in preterm infants.

PubMed
Good health and well-being
Neonatal Respiratory Health Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon